Botox 100 unit vials
Ended Awarded
- Contract number
- SPE2DB26FR1HD
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $2,313
Award facts
- Contract value 100% obligated
- $2,312.85 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $2,312.85 to DMS Pharmaceutical Group Inc. for Botox 100 unit vials on October 28, 2025, with an ultimate completion date of November 19, 2025. This firm fixed-price delivery order was issued without a set-aside designation, enabling the woman-owned small business pharmaceutical wholesaler to compete in unrestricted federal procurement. DMS Pharmaceutical Group Inc., headquartered in Park Ridge, Illinois, has been registered in the System for Award Management since 2001 and maintains substantial contracting activity with the Defense Logistics Agency's Medical Supply Chain division, supplying a comprehensive portfolio of pharmaceuticals and medical consumables to support Department of Defense healthcare operations.
This delivery order was issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a multi-billion dollar acquisition strategy that establishes multiple regional prime vendor contractors to supply pharmaceuticals to military healthcare facilities worldwide. The underlying IDC, designated contract SPE2DR and awarded on November 13, 2025, carries a $499.999 billion ceiling value and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. Through this framework, DMS Pharmaceutical Group is positioned to deliver diverse and specialized pharmaceutical requirements, including branded and generic medications, biologics, and medical consumables, to support recurring medical supply needs across the global Department of Defense military medical system.
Quick answers
Who was awarded contract SPE2DB26FR1HD?
SPE2DB26FR1HD was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 28, 2025.
How much is contract SPE2DB26FR1HD worth?
The government has obligated $2,313 on SPE2DB26FR1HD.
Is contract SPE2DB26FR1HD an order under another contract?
Yes. SPE2DB26FR1HD is a delivery order under SPE2DB22D9251, an indefinite delivery contract.
Was contract SPE2DB26FR1HD competed?
The extent of competition for SPE2DB26FR1HD was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award